(Q38287219)

1 September 2017

1 reference

title

Levodopa: effect on cell death and the natural history of Parkinson's disease (English)

1 reference

1 September 2017

1 reference

1 reference

Charles Warren Olanow

series ordinal

1

object named as

C Warren Olanow

1 reference

1 September 2017

language of work or name

English

0 references

publication date

11 December 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

30

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

37-44

1 reference

The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra

1 September 2017

cites work

1 reference

Increased nigral iron content in postmortem parkinsonian brain

21 January 2018

1 reference

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

21 January 2018

1 reference

Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study

21 January 2018

1 reference

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease

21 January 2018

1 reference

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease

21 January 2018

1 reference

Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?

21 January 2018

1 reference

Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease

21 January 2018

1 reference

Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line

21 January 2018

1 reference

Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development

21 January 2018

1 reference

Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l-DOPA and Carbidopa Chronically

21 January 2018

1 reference

Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys

21 January 2018

1 reference

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

21 January 2018

1 reference

Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions

21 January 2018

1 reference

Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study

21 January 2018

1 reference

Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress

21 January 2018

1 reference

Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines

21 January 2018

1 reference

Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses

21 January 2018

1 reference

Oxidative stress and the pathogenesis of Parkinson's disease

21 January 2018

1 reference

Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period

21 January 2018

1 reference

Does levodopa accelerate the pathologic process in Parkinson disease brain?

21 January 2018

1 reference

Levodopa toxicity and Parkinson disease: still a need for equipoise

21 January 2018

1 reference

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

21 January 2018

1 reference

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

Slowing Parkinson's disease progression: recent dopamine agonist trials

21 January 2018

1 reference

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

21 January 2018

1 reference

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

21 January 2018

1 reference

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

21 January 2018

1 reference

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

21 January 2018

1 reference

Parkinson's disease, levodopa-use and the risk of melanoma

21 January 2018

1 reference

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

Mortality in Parkinson's disease: a systematic review and meta-analysis

21 January 2018

1 reference

Levodopa in the treatment of Parkinson's disease: a consensus meeting

21 January 2018

1 reference

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.26119

1 reference

1 September 2017

1 reference